학술논문
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Document Type
Article
Author
Source
In European Journal of Cancer May 2023 184:39-47
Subject
Language
ISSN
0959-8049